GlassScriptPhysician profile
Jerry B Williams
NPI 1699746552
$6,681.91
in general payments reported to CMS, 2019-2025
29 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $578 · 2021: $1,123 · 2022: $1,339 · 2023: $1,161 · 2024: $921 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,104.86 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $983.56 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $696.10 | 2019-2025 | |
| Pfizer INC. | $671.68 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $426.78 | 2021-2025 | Verquvo |
| Amgen INC. | $420.79 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.04 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $301.62 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $276.92 | 2020-2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $241.17 | 2019-2024 | Xarelto |
| Medtronic, INC. | $184.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $148.27 | 2019-2024 | |
| Inspire Medical Systems, INC. | $146.42 | 2025 | Inspire |
| Amarin Pharma, INC. | $134.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.65 | 2019-2024 | Eliquis, Camzyos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $115.62 | 2023-2024 | |
| Boston Scientific Corporation | $72.23 | 2021-2025 | General - Brady |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.74 | 2022-2025 | Lifevest |
| Roche Diagnostics Corporation | $50.00 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $45.87 | 2023 | Inpefa |
| Abbott Laboratories | $24.53 | 2021 | |
| Impulse Dynamics (USA) INC. | $23.28 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $20.21 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $18.85 | 2024 | |
| Daiichi Sankyo INC. | $17.76 | 2020 | |
| Irhythm Technologies, INC. | $16.70 | 2022 | |
| Preventice Services, LLC | $15.79 | 2020 | |
| Esperion Therapeutics, INC. | $14.83 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.63 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.